+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tuberculosis Drugs Market - Global Forecast 2026-2032- Product Image
Tuberculosis Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Tuberculosis Drugs Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4985928
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Tuberculosis Drugs Market is projected to reach USD 2.34 Billion in 2026. It is expected to continue growing at a CAGR of 5.03%, reaching USD 3.14 Billion by 2032.

Tuberculosis drugs remain central to global infectious disease control as TB continues to rank among the world’s deadliest communicable diseases. The World Health Organization (WHO) reported that an estimated 10.8 million people developed TB in 2023 and 1.25 million people died from the disease, underscoring sustained need for first-line tuberculosis treatment, drug-resistant TB regimens, pediatric TB formulations, and adherence-enabling delivery models.

Commercial priorities are being shaped by two concurrent realities: most drug-susceptible TB is still treated with established rifamycin-, isoniazid-, pyrazinamide-, and ethambutol-based regimens, while multidrug-resistant TB and rifampicin-resistant TB require newer all-oral options such as bedaquiline-, pretomanid-, linezolid-, and moxifloxacin-containing combinations. For pharmaceutical manufacturers, global health procurers, and public-sector buyers, opportunity is tied less to premium pricing and more to reliable supply, differentiated formulations, quality assurance, pharmacovigilance, and alignment with WHO tuberculosis treatment guidelines.

Market Shifts Reshaping TB Therapeutics

The tuberculosis drugs landscape is shifting from long, injectable-heavy treatment pathways toward shorter, all-oral, patient-centered regimens. WHO recommendations for six-month BPaLM and BPaL-based regimens for eligible multidrug-resistant or rifampicin-resistant TB patients have materially changed procurement expectations by increasing the strategic relevance of bedaquiline, pretomanid, linezolid, and fluoroquinolone supply continuity.

At the same time, TB prevention and latent tuberculosis infection treatment are gaining policy attention in low-incidence markets and among high-risk populations. Shorter preventive therapy regimens using rifapentine and isoniazid are improving completion rates versus longer isoniazid monotherapy, creating demand for formulations and distribution models that fit community-based care, migrant health programs, HIV services, occupational screening initiatives, and contact-tracing programs.

AI Impact on TB Drug Discovery and Care

Artificial intelligence is beginning to influence the tuberculosis drugs ecosystem by improving screening efficiency, accelerating target identification, and strengthening pharmacovigilance. WHO has recognized computer-aided detection for chest radiography as a screening tool in defined settings, which can expand timely identification of people who require confirmatory testing and appropriate TB therapy initiation when linked to reliable diagnostic and medicine access pathways.

For manufacturers and research organizations, AI-enabled molecular modeling, literature mining, resistance prediction, safety-signal detection, and trial-site optimization can reduce friction in TB drug development. However, measurable commercial and clinical impact depends on validation, regulatory acceptance, representative datasets, and integration with laboratory confirmation, because AI cannot substitute for microbiological diagnosis, drug-susceptibility testing, or evidence from controlled clinical trials.

Regional Demand Patterns for TB Drugs

Asia-Pacific is the most consequential demand center for tuberculosis drugs because WHO identifies India, Indonesia, China, the Philippines, Pakistan, Bangladesh, and other regional markets among the major contributors to global TB incidence. India alone accounts for roughly one-quarter of the global TB burden, making public procurement, domestic manufacturing, fixed-dose combinations, and shorter treatment adoption central to regional access. In parallel, high-burden Asia-Pacific settings are prioritizing diagnostic scale-up, private-sector engagement, pediatric TB care, and drug-resistant TB treatment capacity.

North America and Europe have lower TB incidence but remain important for latent tuberculosis infection management, migrant health programs, specialty drug-resistant TB care, strict regulatory oversight, and pharmacovigilance requirements. Latin America, led by Brazil, Peru, and Mexico, shows sustained need for public-sector treatment supply, adherence programs, and urban TB control. The Middle East’s tuberculosis drug demand is influenced by expatriate and migrant worker screening, cross-border mobility, and centralized hospital procurement, while Africa remains a high-priority region because TB-HIV coinfection, diagnostic gaps, financing constraints, and medicine availability continue to shape demand for affordable first-line drugs and scalable drug-resistant TB regimens.

Strategic Group-Level TB Drug Signals

ASEAN is strategically important for tuberculosis drug suppliers because Indonesia, the Philippines, Vietnam, Myanmar, and Thailand combine high disease burden with expanding national TB programs and donor-supported procurement. The region’s market dynamics favor quality-assured generics, pediatric formulations, fixed-dose combinations, shorter regimens, and decentralized care models that support treatment completion across urban, rural, and island geographies.

The GCC is a lower-incidence but operationally important group where expatriate health screening, hospital procurement, and antimicrobial stewardship influence demand for tuberculosis therapeutics. The European Union and G7 markets emphasize regulatory compliance, latent TB management, surveillance-led treatment, and specialty care for drug-resistant disease, while NATO countries also prioritize infectious disease surveillance, medical readiness, and resilient medicine supply chains. BRICS is the most consequential group for volume and policy influence because India, China, Russia, Brazil, and South Africa collectively include major TB and drug-resistant TB burdens, significant domestic manufacturing capacity, and large public-sector purchasing systems.

Country-Level TB Drug Opportunities

In the United States, the CDC reported 9,633 TB cases in 2023, reinforcing demand for targeted active TB treatment, latent tuberculosis infection therapy, and rapid access to drug-resistant TB expertise. Canada and Australia maintain low-incidence profiles but require steady supply for foreign-born populations, Indigenous communities, and specialized public health programs. Mexico and Brazil remain key Latin American markets because urban transmission, social determinants, and public-sector treatment programs sustain demand for quality-assured first-line medicines and adherence support.

Across Europe, the United Kingdom, Germany, France, Italy, and Spain focus on surveillance-led treatment, migrant screening, latent TB strategies, and guideline-compliant medicine access, while Russia remains particularly significant for multidrug-resistant TB and rifampicin-resistant TB management. China and India are decisive volume markets, with India driving the largest global treatment need and China emphasizing scale, surveillance, and domestic production. Japan and South Korea are mature healthcare markets where aging populations, low-to-moderate incidence, hospital-based care, and strong regulatory expectations shape demand for reliable TB therapeutics.

Recommendations for TB Drug Leaders

Industry leaders should prioritize supply resilience for rifampicin, isoniazid, pyrazinamide, ethambutol, rifapentine, bedaquiline, pretomanid, linezolid, and moxifloxacin, because stockouts can directly affect treatment completion and resistance prevention. Companies should align portfolios with WHO guidance, national essential medicines lists, pharmacovigilance expectations, and Global Drug Facility quality requirements to strengthen eligibility for public procurement.

Manufacturers can improve competitiveness by investing in heat-stable formulations, pediatric dispersible products, fixed-dose combinations, shorter-regimen packaging, robust quality systems, and country-specific access partnerships. R&D leaders should focus on safer sterilizing regimens, resistance-sparing combinations, long-acting or adherence-supporting approaches, and biomarkers that shorten trials while maintaining rigorous evidence standards.

Evidence-Based Research Methodology

This executive summary is built from verified public-health and regulatory evidence, including WHO Global TB Programme data, national TB surveillance agencies, peer-reviewed clinical trial evidence, FDA and EMA product information, treatment guideline updates, and procurement-oriented sources such as the Stop TB Partnership Global Drug Facility.

The methodology applies triangulation across epidemiology, treatment algorithms, country burden, procurement practices, regulatory pathways, resistance patterns, and pipeline signals. Insights are validated through cross-comparison of incidence trends, drug-resistance burden, policy adoption, therapy availability, and guideline evolution to ensure that conclusions reflect documented market realities rather than speculative estimates.

Strategic Conclusion

The tuberculosis drugs market is defined by persistent disease burden, rising attention to drug-resistant TB, and the transition toward shorter, all-oral, patient-centered regimens. Demand remains highest where TB incidence is concentrated, but high-income markets also play an important role in latent tuberculosis infection treatment, innovation adoption, pharmacovigilance, and regulatory standard-setting.

Organizations that combine reliable supply, WHO-aligned portfolios, evidence-based innovation, quality-assured manufacturing, and access-focused partnerships will be best positioned to serve public health needs while building durable relevance in tuberculosis therapeutics.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Tuberculosis Drugs Market, by Tuberculosis Type
7.1. Introduction
7.2. Active Tuberculosis
7.2.1. Drug-Susceptible Tuberculosis
7.2.1.1. Pulmonary Tuberculosis
7.2.1.2. Extrapulmonary Tuberculosis
7.2.2. Drug-Resistant Tuberculosis
7.2.2.1. Multidrug-Resistant Tuberculosis
7.2.2.2. Extensively Drug-Resistant Tuberculosis
7.3. Latent Tuberculosis Infection
8. Tuberculosis Drugs Market, by Route Of Administration
8.1. Introduction
8.2. Injectable
8.3. Oral
9. Tuberculosis Drugs Market, by Drug Class
9.1. Introduction
9.2. Rifamycins
9.3. Fluoroquinolones
9.4. Aminoglycosides
9.5. Oxazolidinones
9.6. Nitroimidazoles
10. Tuberculosis Drugs Market, by Age Group
10.1. Introduction
10.2. Pediatrics
10.3. Adults
11. Tuberculosis Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Tuberculosis Drugs Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Specialty Clinics
12.4. Tuberculosis Treatment Centers
12.5. Homecare Settings
13. Tuberculosis Drugs Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Tuberculosis Drugs Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Tuberculosis Drugs Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. France
15.8. Australia
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Brazil
15.13. Russia
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Johnson & Johnson Services, Inc.
17.2. Hikma Pharmaceuticals PLC
17.3. Sanofi S.A.
17.4. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
17.5. Cipla Limited
17.6. GlaxoSmithKline PLC
17.7. Eli Lilly and Company
17.8. Viatris Inc.
17.9. FarmaVision Healthcare
17.10. SiNi Pharma Pvt Ltd
17.11. AstraZeneca PLC
17.12. Cadila Pharmaceuticals Limited
17.13. Fresenius SE & Co. KGaA
17.14. Lupin Limited
17.15. Macleods Pharmaceuticals Ltd.
17.16. Merck & Co., Inc.
17.17. Otsuka Pharmaceutical Co., Ltd.
17.18. Pfizer Inc.
17.19. Sandoz International GmbH
17.20. Sun Pharmaceutical Industries Ltd.
17.21. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL TUBERCULOSIS DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL TUBERCULOSIS DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL TUBERCULOSIS DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL TUBERCULOSIS DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 11. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 13. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL TUBERCULOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL TUBERCULOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL TUBERCULOSIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ACTIVE TUBERCULOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ACTIVE TUBERCULOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ACTIVE TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL DRUG-SUSCEPTIBLE TUBERCULOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL DRUG-SUSCEPTIBLE TUBERCULOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL DRUG-SUSCEPTIBLE TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL PULMONARY TUBERCULOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL PULMONARY TUBERCULOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL PULMONARY TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL EXTRAPULMONARY TUBERCULOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL EXTRAPULMONARY TUBERCULOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL EXTRAPULMONARY TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL DRUG-RESISTANT TUBERCULOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL DRUG-RESISTANT TUBERCULOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL DRUG-RESISTANT TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL LATENT TUBERCULOSIS INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL LATENT TUBERCULOSIS INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL LATENT TUBERCULOSIS INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL RIFAMYCINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL RIFAMYCINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL RIFAMYCINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL OXAZOLIDINONES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL OXAZOLIDINONES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL OXAZOLIDINONES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL NITROIMIDAZOLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL NITROIMIDAZOLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL NITROIMIDAZOLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL PEDIATRICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL PEDIATRICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL PEDIATRICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ADULTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL TUBERCULOSIS TREATMENT CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL TUBERCULOSIS TREATMENT CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL TUBERCULOSIS TREATMENT CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 92. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 94. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 95. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 96. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 97. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 98. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 99. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 100. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 101. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 112. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 122. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 124. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 125. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 126. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 127. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 128. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 129. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 130. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 131. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 132. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 134. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 140. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 141. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 143. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 145. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 146. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 147. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 148. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 149. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 150. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 151. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 152. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 153. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 154. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 155. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 156. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 157. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 158. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 159. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 160. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 161. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 162. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 163. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 164. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 165. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 166. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 167. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 168. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 169. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 170. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 171. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 172. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 183. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 184. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 185. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 186. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 187. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 188. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 189. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 190. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 191. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 192. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 193. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 194. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 195. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 196. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 197. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 198. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 199. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 200. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 201. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 202. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 203. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 204. CHINA TUBERCULOSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 205. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 206. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 207. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 208. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 209. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 210. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 211. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 212. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 213. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 214. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 215. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 216. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 217. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 218. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 219. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 220. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 221. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 222. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 223. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 224. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 225. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 226. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 227. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 228. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 229. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 230. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 231. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 232. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 233. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 234. INDIA TUBERCULOSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 235. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 236. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 237. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 238. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 239. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 240. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 241. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 242. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 243. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 244. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 245. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 246. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 247. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 248. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 249. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 250. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 251. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 252. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 253. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 254. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 255. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 256. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 257. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 258. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 259. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 260. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 261. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 262. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 263. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 264. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 265. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 266. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 267. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 268. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 269. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 270. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 271. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 272. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 273. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 274. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 275. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 276. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 277. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 278. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 279. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 280. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 281. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 282. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 283. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 284. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 285. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 286. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 287. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 288. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 289. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 290. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 291. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 292. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 293. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 294. ITALY TUBERCULOSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 295. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 296. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 297. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 298. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 299. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 300. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 301. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 302. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 303. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 304. CANADA TUBERCULOSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 305. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 306. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 307. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 308. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 309. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 310. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 311. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 312. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 313. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 314. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 315. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 316. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 317. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 318. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 319. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 320. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 321. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 322. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 323. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 324. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 325. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 326. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 327. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 328. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 329. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 330. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 331. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 332. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 333. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 334. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 335. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 336. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 337. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 338. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 339. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 340. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 341. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 342. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 343. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 344. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 345. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2017-2032 (USD MILLION)
TABLE 346. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 347. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 348. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2017-2032 (USD MILLION)
TABLE 349. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 350. SP

Companies Mentioned

  • Johnson & Johnson Services, Inc.
  • Hikma Pharmaceuticals PLC
  • Sanofi S.A.
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Cipla Limited
  • GlaxoSmithKline PLC
  • Eli Lilly and Company
  • Viatris Inc.
  • FarmaVision Healthcare
  • SiNi Pharma Pvt Ltd
  • AstraZeneca PLC
  • Cadila Pharmaceuticals Limited
  • Fresenius SE & Co. KGaA
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.34 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.14 Billion
Compound Annual Growth Rate5.0%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Ocular Tuberculosis Therapeutics Market - Global Forecast 2026-2032 - Product Image

Ocular Tuberculosis Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Multidrug-resistant Tuberculosis Therapeutics Market - Global Forecast 2026-2032 - Product Image

Multidrug-resistant Tuberculosis Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Mycobacterium Tuberculosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Mycobacterium Tuberculosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 215 Pages
  • Global
From
Anti-Tuberculosis Therapeutics Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035) - Product Image

Anti-Tuberculosis Therapeutics Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

  • Report
  • 400 Pages
  • Global
From
Tuberculosis Treatment Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035) - Product Image

Tuberculosis Treatment Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

  • Report
  • 400 Pages
  • Global
From

About the Tuberculosis Drug Market

The Tuberculosis Drug market is a subset of the larger Respiratory Drug market. It is composed of drugs used to treat tuberculosis, a bacterial infection that affects the lungs and other parts of the body. These drugs are typically antibiotics, such as isoniazid, rifampicin, and ethambutol, and are used in combination to treat the infection. The drugs are usually taken for a period of six to nine months, and are often used in combination with other treatments, such as surgery or chemotherapy. The Tuberculosis Drug market is highly competitive, with many companies offering different combinations of drugs. Some of the major players in the market include Pfizer, GlaxoSmithKline, Sanofi, Merck, and Novartis. Other companies, such as Cipla, Lupin, and Sun Pharmaceuticals, also offer a range of tuberculosis drugs. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.